Skip to main content
Top
Published in:

05-05-2024 | Acute Pancreatitis | Review article

The effect of incretin-based drugs on the riks of acute pancreatitis: a review

Authors: Agata Czaplicka, Beata Kaleta

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2024

Login to get access

Abstract

Objectives

In recent years, new hypoglycaemic drugs that affect the incretin system have become increasingly popular in the treatment of type 2 diabetes mellitus (T2DM): glucagon-like receptor 1 agonists (GLP1RAs), dipeptidyl peptidase 4 inhibitors (DPP4is) and the recently developed dual glucagon-like receptor 1 agonist and glucose-dependent insulinotropic polypeptide (tirzepatide). Their main role of these drugs is to normalise blood glucose levels. In addition, GLP1RAs are approved for the treatment of excessive body weight. The efficacy of drugs affecting the incretin system is well described in the literature, however, there are still only few reports about their safety. This review aims to summarize the results of current research and meta-analyses on risk of acute pancreatitis (AP) during incretin-affecting drugs treatment.

Methods

A narrative review was performed using present literature in an attempt to identify the relationship between AP and incretin-affecting drugs. The following keywords were used: acute pancreatitis, glucagon-like receptor 1 agonists, dipeptidyl peptidase 4 inhibitors and tirzepatide.

Results

It was demonstrated that the use of DPP4is is safe for the majority of patients with T2DM, whereas a risk of AP should be noted in case of GLP1RAs therapy. To date, most studies found no significant association between tirzepatide therapy and the increased risk of AP.

Conclusion

The majority of studies have shown that DPP4is, GLP1RAs and tirzepatide are effective and safe in most T2DM patients. However, the follow-up time for patients treated with tirzepatide is short, therefore more studies are required to confirm the safety of this drug.
Literature
8.
29.
go back to reference Scirica BM, Im K, Murphy SA, Kuder JF, Rodriguez DA, Lopes RD, et al. Re-adjudication of the Trial evaluating Cardiovascular outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. Clin Cardiol. 2022;45(7):794–801. https://doi.org/10.1002/clc.23844.CrossRefPubMedPubMedCentral Scirica BM, Im K, Murphy SA, Kuder JF, Rodriguez DA, Lopes RD, et al. Re-adjudication of the Trial evaluating Cardiovascular outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. Clin Cardiol. 2022;45(7):794–801. https://​doi.​org/​10.​1002/​clc.​23844.CrossRefPubMedPubMedCentral
42.
44.
49.
go back to reference Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE, et al. 2 DIABETES MANAGEMENT ALGORITHM– 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020;26(1):107–39. https://doi.org/10.4158/CS-2019-0472.CrossRefPubMed Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE, et al. 2 DIABETES MANAGEMENT ALGORITHM– 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020;26(1):107–39. https://​doi.​org/​10.​4158/​CS-2019-0472.CrossRefPubMed
50.
go back to reference Yabe D, Kuwata H, Kaneko M, Ito C, Nishikino R, Murorani K, et al. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes Obes Metab. 2015;17(4):430–4. https://doi.org/10.1111/dom.12381.CrossRefPubMed Yabe D, Kuwata H, Kaneko M, Ito C, Nishikino R, Murorani K, et al. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes Obes Metab. 2015;17(4):430–4. https://​doi.​org/​10.​1111/​dom.​12381.CrossRefPubMed
Metadata
Title
The effect of incretin-based drugs on the riks of acute pancreatitis: a review
Authors
Agata Czaplicka
Beata Kaleta
Publication date
05-05-2024
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2024
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-024-01430-6

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more